Press Releases

Advances include a rapid vaccine analysis platform, companion diagnostic for solid tumors, and bioanalytical validation methods for biomarkers and companion diagnostics

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a virtual Emerging Technologies in Diagnostics Symposium from 10 a.m. to 1 p.m. ET on Thursday, Oct. 29.

“The diagnostic assay landscape is changing rapidly as the demand for faster, less expensive, more precise diagnostics continues to grow,” said Cathie G. Miller, PhD, director of product marketing, personalized medicine at BioIVT. “We wanted to take this opportunity to showcase some of the exciting new technologies that are helping to accelerate in vitro and companion diagnostic development. This event also reflects BioIVT’s commitment to helping bring effective diagnostics to market faster to improve human and animal health.”

Dr. Miller will introduce three guest speakers and describe the integral role that BioIVT’s biological specimens and specialty research services are playing in the development of new diagnostic assays.

Rafiq Islam, MS, regional vice president, pharmaceutical development services, at Smithers, will lead the first technical session, discussing bioanalytical method validation for biomarkers and companion diagnostics.

He will be followed by Kevin Kohlmeier, BS, director of marketing at IndevR, Inc., who will address rapid vaccine analysis. InDevR's VaxArray Platform has been shown to speed vaccine analysis, improve data quality, eliminate assay development, and standardize assays used for vaccine testing.

Then, Heather Tomlinson, PhD, director of clinical diagnostics at Promega Corporation, will discuss how the company used an established, on-market, PCR-based microsatellite instability assay to develop OncoMate™ MSI, its companion diagnostic for immune checkpoint inhibitors for all solid tumors regardless of their site of origin.

Dr. Miller will also describe how BioIVT is able to provide high quality, ethically sourced biospecimens, representing a wide range of diseases and health conditions, to accelerate the development of diagnostic assays, companion diagnostics, and point-of-care devices. They include board certified, pathologist reviewed, ASTERAND® human tissue samples, KEYSTONE™ Bulk control and calibrator plasma and other biofluids from specific donor cohorts.

Interested parties can register for this complimentary online event at https://info.bioivt.com/ivd-symp-reg-lp.

About BioIVT

BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.